BlueSphere Bio Presents New Data Supporting the Potential of its TCXpress™ Platform at the 2022 AACR Meeting
TCXpress™ identified a diverse set of novel T-cell receptors (TCRs) with in vitro reactivity against…
Month: April 2022
X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting
ZURICH, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — Araris Biotech AG, a company pioneering a…
Genocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022
GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with…
Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022
MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition…
Umoja Biopharma Presents Data on its iPSC-Based Cell Therapy Platform at the American Association for Cancer Research (AACR) Annual Meeting 2022
Data demonstrates the potential for de novo engineering of novel synthetic cytotoxic effector cells that show significant…
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide…
Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual Meeting
CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company…
Calithera Presents Data Highlighting Discovery of Novel Series of Promising Synthetic Lethal Compounds
Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their…
iOnctura Presents Data at AACR Demonstrating its Unique Mechanism of Action for Clinical Stage ATX Inhibitor IOA-289
GENEVA, Switzerland, April 08, 2022 (GLOBE NEWSWIRE) — iOnctura SA, a clinical-stage oncology company targeting…
Adaptimmune Presents MAGE-A4 Expression Data from its Screening Protocol at AACR Confirming Expression Across a Broad Range of Solid Tumors
– Data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer…
Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND Clearance
First data presentation on AGEN1571 shows strong adaptive and innate immune responses Preclinical data indicate…
iTeos Presents New Data for Anti-TIGIT Antibody, EOS-448/GSK4428859A, at the AACR Annual Meeting 2022
Treatment with EOS-448 results in a decrease of TIGIT-positive cells in tumor biopsies, the first…
Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to…
Senti Bio Presents New Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at AACR Annual Meeting
– Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of…
Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting
– ONCR-021 and ONCR-788 demonstrate robust preclinical anti-tumor efficacy following IV-administration – – vRNA Immunotherapy…
Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting
Anti-tumor data from systemic novel TREX1 inhibitors designed to activate the STING pathway selectively in…
Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting
Preclinical data demonstrate that edited iNK cells result in increased persistence, enhanced anti-tumor activity and…
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
– ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent…
Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability
Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal…